科研之友
微信
新浪微博
Facebook
分享链接
摘要
The extent and presentation of advanced forms or drug-resistant tuberculosis (TB), as well as unduly extended and toxic defaulter-generating regimens, present great challenges to TB treatment. The pipeline for approval of new anti-TB drugs has yielded only one drug with a novel mode of action since 1974. Besides enhanced efficacy, compatibility with other conventionally used drugs against TB and its common comorbidities such as HIV and type 2 diabetes is an important prerequisite. This review describes new and/or repurposed drugs currently being tested and outlines principles governing their integration into efficacious and safe treatment regimens.
- 出版日期2015-1
